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Abstract
Background
Stroke is associated with the development of cognitive impairment and dementia. We
assessed the effect of intensive blood pressure (BP) and/or lipid lowering on cognitive out-
comes in patients with recent stroke in a pilot trial.
Methods
In a multicentre, partial-factorial trial, patients with recent stroke, absence of dementia, and
systolic BP (SBP) 125–170 mmHg were assigned randomly to at least 6 months of intensive
(target SBP <125 mmHg) or guideline (target SBP <140 mmHg) BP lowering. The subset of
patients with ischaemic stroke and total cholesterol 3.0–8.0 mmol/l were also assigned ran-
domly to intensive (target LDL-cholesterol <1.3 mmol/l) or guideline (target LDL-c <3.0
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mmol/l) lipid lowering. The primary outcome was the Addenbrooke’s Cognitive Examination-
Revised (ACE-R).
Results
We enrolled 83 patients, mean age 74.0 (6.8) years, and median 4.5 months after stroke.
The median follow-up was 24 months (range 1–48). Mean BP was significantly reduced with
intensive compared to guideline treatment (difference –106/–55 mmHg; p<001), as was
total/LDL-cholesterol with intensive lipid lowering compared to guideline (difference –054/
–044 mmol/l; p<001). The ACE-R score during treatment did not differ for either treatment
comparison; mean difference for BP lowering -3.6 (95% CI -9.7 to 2.4), and lipid lowering
4.4 (95% CI -2.1 to 10.9). However, intensive lipid lowering therapy was significantly associ-
ated with improved scores for ACE-R at 6 months, trail making A, modified Rankin Scale
and Euro-Qol Visual Analogue Scale. There was no difference in rates of dementia or seri-
ous adverse events for either comparison.
Conclusion
In patients with recent stroke and normal cognition, intensive BP and lipid lowering were fea-
sible and safe, but did not alter cognition over two years. The association between intensive
lipid lowering and improved scores for some secondary outcomes suggests further trials are
warranted.
Trial Registration
ISRCTN ISRCTN85562386
Introduction
Stroke is complicated by cognitive impairment in up to 92% of survivors,[1] and dementia in
30%. Post stroke cognitive impairment (PSCI) more commonly affects executive dysfunction,
and is associated with increased mortality and decreased quality of life.[2, 3] Despite these seri-
ous complications, which are devastating to patients and their family and economically costly
to society, the evidence base for the prevention of PSCI and post-stroke dementia (PSD) is lim-
ited. Many potential interventions for preventing cognitive decline have been proposed,
including blood pressure (BP) and lipid lowering, antiplatelet agents, anti-oxidant vitamins,
and cholinesterase inhibitors.[4] Of these, lowering BP and blood lipid levels are priorities for
testing as elevated BP and cholesterol are common after stroke, effective therapies are available,
and consistent trial evidence supports drug treatment to prevent recurrent vascular events.[5–
7] As a result, most patients need their BP lowered, and those with ischaemic stroke usually
need a statin, as recommended in guidelines.[8, 9]
Although the effect of BP lowering on cognitive impairment and dementia has been
assessed in several trials, the results are conflicting and only hypothesis-generating since cog-
nitive outcomes were never the primary outcome in these trials. In a post-stroke population,
the PROGRESS trial found that perindopril, with or without indapamide (versus placebo),
reduced PSCI and PSD, largely through preventing stroke recurrence.[10, 11] In contrast,
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both the PRoFESS (telmisartan versus placebo) and SPS3 (intensive versus guideline BP lower-
ing in patients with subcortical stroke) trials reported no benefit of antihypertensive therapy
on cognition post stroke.[12–15] A meta-analysis of these trials, and others not involving
stroke patients, found that BP lowering was associated with less cognitive decline (assessed as
change in the Mini-Mental State Examination, MMSE) but not with reduced dementia;[4] a
meta-regression of the same studies suggested that there might be a ‘J-shaped’ curve linking
the development of dementia with difference in BP between treatment groups.[4] In a meta-
analysis limited to patients without stroke, BP lowering was associated with less cognitive
decline but not dementia.[16]
In respect of lipid lowering, there is no positive evidence that statins (currently the main
lipid intervention) prevent cognitive decline or dementia, as reported in secondary analyses
from the PROSPER (pravastatin) and HPS (simvastatin) trials.[17–19] Overall, systematic
reviews of trials using statins to prevent or treat dementia have reported no benefit.[4, 20, 21]
However, systematic reviews of observational and other studies raised the possibility that stat-
ins might reduce dementia.[22, 23]
In view of the uncertainties surrounding the potential for BP and lipid lowering to reduce
PSCI and PSD, and yet the need for most patients to receive antihypertensive and lipid lower-
ing therapy for the purposes of secondary prevention, the pilot PODCAST randomised con-
trolled partial-factorial trial compared intensive versus guideline BP lowering, and intensive
versus guideline lipid lowering, on cognition and other functional measures, and the main
results are reported here.
Methods
PODCAST was a pilot multicentre prospective randomised open-label blinded-endpoint
(PROBE) trial. Details of the design, statistical analysis plan and baseline data have been pub-
lished;[24, 25] the full protocol (S2 File) is available online (http://www.podcast-trial.org/
PodcastProtocolV16.pdf). In brief, patients with a recent stroke were randomly assigned to at
least 6 months of management with intensive BP lowering or guideline BP lowering. In addi-
tion, the subset of patients with ischaemic stroke were randomly assigned to intensive vs
guideline lipid lowering in a partial-factorial design.[24]
Patients were eligible for the trial if they had an ischaemic or haemorrhagic stroke within
the previous 3 to 7 months, were aged over 70 with a telephone-Mini Mental State Examina-
tion (t-MMSE) >16 or were aged 60–70 with t-MMSE 17–20 (the latter so as to enrich the
population with stroke survivors at greater risk of developing cognitive impairment and
dementia), were functionally independent (modified Rankin Scale, mRS 0–2), had a systolic
BP of 125–170 mmHg, had an informant who could provide information on the IQ-CODE,
[26] and had capacity and were willing to give consent.[24] Patients with an ischaemic stroke
also had to have a total cholesterol of 3–8 mmol/l. The diagnosis of the stroke must have been
confirmed with CT or MRI using standard imaging techniques and done within 10 days of the
index event to allow differentiation of stroke type. Key exclusion criteria included an existing
diagnosis of dementia, need for intensive BP or lipid control, intolerance to high intensity
statins, need for treatment with an acetyl-cholinesterase inhibitor, dementia, subarachnoid
haemorrhage, secondary intracranial haemorrhage, insufficient capacity to provide informed
consent or to complete study measures, profound deafness, chronic renal failure or eGFR<45
(or eGFR <37 in people of African/Afro-Caribbean origin), liver disease or ALT >3 times the
upper limit of normal, ongoing participation in a clinical trial of an investigational medicinal
product and/or device, any serious medical co-morbidity, or familial stroke associated with
dementia.[24]
Intensive Blood Pressure and Lipid Lowering for Preventing Cognitive Decline after Stroke
PLOS ONE | DOI:10.1371/journal.pone.0164608 January 17, 2017 3 / 21
The study was approved by the United Kingdom (UK) National Research Ethics Commit-
tee East Midlands–Nottingham 1. Hospital local research & development offices at each site
provided local approval and oversight. As a management rather than treatment trial, the study
did not fall under the remit of the UK Medicines and Healthcare Products Regulatory Author-
ity. The trial was overseen by a trial steering committee, this including two independent mem-
bers and three patient & carer representatives. The day-to-day conduct of the trial was run by
a trial management committee that was based at the coordinating centre in Nottingham, UK.
An independent data monitoring committee reviewed unmasked data on three occasions. We
obtained written informed consent from each patient before enrolment and in accordance
with UK regulations. The National Institutes Health Research Stroke Research Network sup-
ported the trial through screening and recruitment of patients.[24]
Randomisation
Investigators entered baseline and follow-up data into a database via a secure web-based ran-
domisation system. The data were checked to confirm the patient’s eligibility in real time, and
the computer system assigned participants, with allocation equally to intensive versus guide-
line BP lowering and, in patients with ischaemic stroke, to intensive versus guideline lipid low-
ering, each for a minimum of 6 months. Treatment assignment was stratified on the basis of
stroke type (ischaemic vs haemorrhagic); and minimised on key prognostic baseline variables:
age, sex, number of antihypertensive drugs, on a statin, presence of dysphasia, Addenbrooke’s
Cognitive Examination-R (ACE-R), systolic BP, total cholesterol, mRS, cortical or subcortical
stroke,[27] evidence of periventricular white matter changes on scan, time since index stroke;
minimisation included a random element in 5% of patients. We used stratification and mini-
misation to ensure that the groups were balanced for prognostic factors, and the random ele-
ment reduced predictability.[24] The randomisation algorithm then presented a treatment
allocation as either intensive versus guideline BP lowering and, when relevant, intensive versus
guideline lipid lowering. Because of the low recruitment rate, the numbers of minimisation
variables were reduced during the trial to four (age, ACE-R, systolic BP, total cholesterol).
Drugs for patients randomised to intensive treatment were prescribed via the recruiting site’s
hospital system, and those randomised to guideline treatment attended their general practi-
tioners for routine treatment.
Procedures
Treatment was started immediately after randomisation, was given daily for at least 6 months,
and consisted of antihypertensive therapy, and lipid lowering therapy in patients with ischae-
mic stroke. Drugs were sourced locally from any licensed manufacturer and given open-label.
Hospital research clinics managed intensive medications with the aim of lowering systolic BP
to<125 mmHg and/or LDL-cholesterol <2.0 mmol/l. General practitioners were requested to
manage patients randomised to guideline treatment(s) according to national or local guide-
lines, with the aim of lowering systolic BP<140 mmHg and/or LDL-cholesterol <3.0 mmol/l.
[24]
Study drugs were stopped when the patient withdrew consent, for safety reasons, or when
unacceptable adverse events developed. All patients received standard care, including oral
antithrombotic drugs (in patients with ischaemic stroke) for secondary prevention.
The PODCAST website was used to record demographic and clinical characteristics. Blood
pressure was measured twice using a validated automated monitor (OMRON Healthcare
Company, Kyoto, Japan) supplied to each site. Sites were asked to provide a trained member
of their research staff who was unaware of treatment assignment to do the post-randomisation
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assessments in hospital clinics. Independent expert assessors, who were masked to treatment
assignment, provided central adjudication: cognitive outcomes (AB, CB, GF); vascular events
(PP, AM, RH); CT and MRI scans (JW, DB); and SAEs, including cause-specific deaths (NS,
TE). Patients who did not receive their assigned treatment or who did not adhere to the proto-
col were followed in full. The coordinating centre (masked to treatment allocation) did the
final central telephone follow-up by October 2014.
Outcomes
Outcomes were measured both in clinic and via telephone. The primary outcome measure was
ACE-R [28, 29] which was assessed at each follow-up clinic. Post stroke cognitive impairment
more commonly affects executive dysfunction and for this reason the ACE-R, which incorpo-
rates executive and attentional tasks, was chosen. As pre-specified secondary cognition mea-
sures, further tests were also administered: Stroop test; Trail-Making Tests A and B; category
fluency (animal naming); Mini-Mental State Examination; Telephone Interview for Cognition
Scale-Modified (TICS-M [30]); premorbid cognitive function assessed in an informant inter-
view using the IQCODE;[26] and dementia (DSM IV). The ACE-R is a brief cognitive screen-
ing tool that is predominantly used to screen for neurodegenerative dementia in memory
clinics. The ACE-R has been used in stable cerebrovascular disease (1 year post-stroke/TIA),
with optimal sensitivities and specificities for detecting mild cognitive impairment (MCI)
achieved at cut-offs between 92 and 94 (ACE-R 92: sensitivity 72%, specificity 79%; ACE-R 94:
sensitivity 83%, specificity 73%).[31] The secondary cognition outcomes were chosen to
address three competing interests: first, to cover multiple domains (e.g. memory, attentional);
second, to be deliverable by telephone; and third, to be in common research use to allow cali-
bration with earlier studies.
Pre-specified non-cognitive secondary outcomes comprised BP; fasting lipids; dependency
(mRS);[32] activities of daily living (Barthel index, BI); mood (short Zung depression score
[33]); health-related quality of life (European quality of life-5 dimensions, EQ-5D,[34] from
which health utility status was calculated [EQ-5D/HUS], and EQ-Visual Analogue Scale); vas-
cular events (stroke, myocardial infarction), health resource utilisation; and disposition. Tele-
phone follow-up included telephone-administered MMSE, TICS-M, mRS, BI, Zung, EQ-5D
and EQ-VAS. The safety outcomes were all-cause case fatality, cause-specific case fatality, and
serious adverse events.
Clinic measurements were performed and recorded by research nurses/coordinators at
each site who were trained (e.g. using videos, start-up meetings). Telephone follow-up was per-
formed centrally, again by trained staff.
Statistical analyses
The original protocol specified recruitment of 600 patients to test feasibility, tolerability and
safety in a start-up phase of a planned larger phase III trial;[24] as such, no formal sample size
calculation was performed. However, limited recruitment of participating sites and NHS fund-
ing of intensive BP/lipid drugs (e.g. atorvastatin) meant that a new target recruitment of 100
participants was set. Ultimately just 83 patients were enrolled. No formal sample size calcula-
tion was performed for the start-up phase.
Treatment intensity was expected to occur through increasing the number of different
drugs and their dose (especially to achieve intensive BP lowering), changing tablets to a more
powerful drug (especially with statins for intensive lipid lowering), and increasing the dose of
tablets up to their maximum. Compliance with these approaches is described both as the num-
ber of tablets participants were taking, and the sum of the dose-adjusted number of tablets
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(sum of tablet dose / maximum licensed dose). By example, the maximum dose of amlodipine
is 10 mg so a dose-adjusted value for 5mg is 0.5. Because outcomes such as mRS, EQ-5D-HUS,
and Barthel index include death as part of their scale (scores of 6 on mRS, 0 on EQ-5D-HUS,
and –5 on the Barthel index), and in case treatment was associated with asymmetric effects on
death and other outcome measures (e.g. more death and less impairment), an extreme value
for death was added to the other outcome scales with scores: –1 for ACE-R, EQ-VAS, MMSE,
MoCA, Stroop accuracy, Stroop correct answers, TICS, Trail making A & B correct answers,
animal naming; 301 for Stroop times; 403 for Trail making A time; 601 for Trail making B
time and 1025 on the Zung depression scale, as used previously.[24, 35, 36]
Effects are reported as a mean difference (MD) with 95% CI. We calculated MD and signifi-
cance with multiple regression on the mean on-treatment score, with adjustment for baseline
value, age, systolic BP, total cholesterol, time since stroke and treatment assignment for the
other factorial intervention. We assessed the heterogeneity of the treatment effects on the
primary outcome in pre-specified subgroups by adding an interaction term to an adjusted
multiple regression model. Other analyses used ordinal or binary logistic regression, or Cox
proportional hazards regression. The nominal level of significance for all analyses was p<005
with no interim analysis. In general, no adjustments were made for multiplicity of testing. We
did analyses with SAS version 9.3 according to the intention-to-treat principle.
Role of the funding source
The trial was funded equally by grants from Alzheimer’s Society and Stroke Association in the
UK. There was no commercial support for the trial, and antihypertensive and lipid lowering
drugs were prescribed by the responsible physician and sourced locally. The grant applicants
conceived and designed the trial and wrote the protocol. Study data were collected, monitored,
and analysed by the PODCAST Coordinating Centre in Nottingham, UK. Analysis, interpreta-
tion, and report writing were done independently of the funders and sponsor. The corre-
sponding author and two other authors (PS, LW) had full access to all the data in the study;
additionally, the corresponding author had final responsibility for the decision to submit for
publication, and is the guarantor for the study. This study is registered as ISRCTN85562386
(http://www.isrctn.com/ISRCTN85562386).
Results
Trial conduct
Between 7 October 2010 and 31 January 2014, 83 patients were enrolled from 19 sites in the
UK (Fig 1). 41 patients were assigned to the intensive BP lowering group and 42 patients were
assigned to the guideline BP group (Table 1). 77 (93%) patients presented with an ischaemic
stroke and were included in the intensive lipid lowering (n = 39) or guideline lipid lowering
(n = 38) groups of the trial. There were 106 screen failures, the commonest reasons being age
between 60–70 and t-MMSE >20 (41%) and systolic BP <125 mmHg (18%).[25] The mean
age was 74.0 years, 23% were female, median time from stroke onset to randomisation was 4.5
months, and mean ACE-R score 86.1. The treatment groups were well balanced at baseline
(Table 1). Protocol violations at baseline were apparent in 4 participants who were recruited
with a mRS >2 (S1 Table). The mean (standard deviation) length of follow-up was 23.9 (8.0)
months in those randomised to intensive BP lowering and 24.3 (10.3) months taking guideline
medications. 5 participants did not have at least one follow-up performed according to the
protocol. During follow-up, 9 patients withdrew from the trial (S2 Table).
Intensive Blood Pressure and Lipid Lowering for Preventing Cognitive Decline after Stroke
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Drug management
The number of antihypertensive tablets in patients randomised to intensive BP lowering rose
from 1.7 at baseline to 2.0 during follow-up, this including 6 participants who were rando-
mised to intensive BP lowering but did not receive it (S1 Table). However, the dose adjusted
number of tablets increased from 1.2 to about 1.7. In patients randomised to guideline BP ther-
apy the number of tablets, and dose-adjusted number of tablets were static at 1.9 and 1.2
respectively. The number of tablets in patients randomised to intensive lipid lowering rose
from 1.1 to about 1.4 (including 11 participants who did not receive intensive lipid lowering,
S1 Table), with a bigger rise in dose-adjusted number of tablets from 0.8 to about 1.3. In
patients randomised to guideline lipid therapy the number of tablets, and dose-adjusted num-
ber of tablets, did not change at 1.0 and 0.5 respectively (S3 Table).
Haemodynamic measures
The mean BP at baseline was 147/82 mmHg and fell in both intensive and guideline BP lower-
ing groups during treatment (Fig 2A). Most of the BP reduction occurred during the first 6
months of treatment, by which time BP was lower in those patients randomised to the inten-
sive BP group by 10.6/55 mmHg (2p<0001/0004) (S4 Table). The difference in systolic BP
between treatment groups exceeded the trial’s target of 10 mmHg. The reduction in BP was
further confirmed in 18 patients who had ambulatory BP monitoring at selected sites, with BP
lower by 10.0/6.3 mmHg in those randomised to intensive BP lowering (S5 Table). The target
systolic BP levels of<125 mmHg in the intensive group and<140 mmHg in the control group
were achieved by only 17 (45.9%, S6 Table) and 22 (55.0%) participants respectively. Heart
rate was 50 beats per min lower in the intensive BP group than in the guideline group at 6
months (2p = 0034, S4 Table).
Fig 1. CONSORT flow diagram of patient randomisation, follow up, outcome, and withdrawals. Screening for
eligibility was not collected routinely. Data are number/Number (%).
doi:10.1371/journal.pone.0164608.g001
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Table 1. Clinical characteristics at randomisation, by intensive vs guideline blood pressure and lipid lowering.
All Intensive BP Guideline BP Intensive lipids Guideline lipids
Number 83 41 42 39 38
Age (years) † 74.0 (6.8) 73.0 (6.5) 75.1 (6.9) 74.2 (6.4) 74.4 (6.9)
Sex, male (%) † 64 (77.1) 33 (80.5) 31 (73.8) 30 (76.9) 31 (81.6)
Time to randomisation [months] † 4.5 [1.3] 4.6 [1.5] 4.4 [1.0] 4.4 [1.4] 4.6 [1.3]
Medical history (%)
Memory problem 34 (44.2) 16 (41.0) 18 (47.4) 10 (27.8) 20 (57.1)
Hypertension, treated 69 (83.1) 36 (87.8) 33 (78.6) 32 (82.1) 31 (81.6)
Hyperlipidaemia 73 (88.0) 34 (82.9) 39 (92.9) 36 (92.3) 32 (84.2)
Diabetes mellitus 17 (20.5) 12 (29.3) 5 (11.9) 8 (20.5) 8 (21.1)
Atrial fibrillation 15 (18.1) 8 (19.5) 7 (16.7) 10 (25.6) 5 (13.2)
Stroke 8 (9.6) 3 (7.3) 5 (11.9) 3 (7.7) 5 (13.2)
IHD 20 (24.1) 11 (26.8) 9 (21.4) 8 (20.5) 11 (28.9)
PAD 5 (6.0) 1 (2.4) 4 (9.5) 4 (10.3) 1 (2.6)
Smoking, ever (%) 56 (67.5) 31 (75.6) 25 (59.5) 24 (61.5) 29 (76.3)
Alcohol [upw] 3 [0,10] 3 [0,10] 3 [0,8] 5 [1,14] 2 [0,7]
Index stroke ‡
Ischaemic (%) 77 (92.8) 38 (92.7) 39 (92.9) 39 (100) 38 (100)
Haemorrhagic (%) 6 (7.2) 3 (7.3) 3 (7.1) 0 (0) 0 (0)
Side, right weakness (%) 30 (47.6) 15 (45.5) 15 (50.0) 19 (59.4) 10 (35.7)
Dysphasia (%) † 23 (27.7) 12 (29.3) 11 (26.2) 9 (23.1) 11 (28.9)
BP drugs, number †
Mode 2 1 2 2 1
Median 2 [1,2] 2 [1,2] 2 [1,2] 2 [1,2] 2 [1,2]
Mean 1.8 (0.9) 1.7 (1.0) 1.9 (0.8) 1.8 (0.9) 1.8 (0.9)
>0 (%) 69 (92.0) 35 (85.4) 34 (100) 31 (93.9) 32 (88.9)
BP drug classes (%)
ACE-I or ARB 39 (52.0) 20 (48.8) 19 (55.9) 19 (57.6) 18 (50.0)
ß-receptor antagonist 18 (24.0) 8 (19.5) 10 (29.4) 10 (30.3) 6 (16.7)
Calcium channel blocker 39 (52.0) 21 (51.2) 18 (52.9) 16 (48.5) 20 (55.6)
Diuretic 20 (26.7) 7 (17.1) 13 (38.2) 10 (30.3) 7 (19.4)
Other 6 (8.0) 2 (4.9) 4 (11.8) 4 (12.1) 1 (2.8)
Lipid tablets (%)
Any statin † 79 (95.2) 40 (97.6) 39 (92.9) 38 (97.4) 37 (97.4)
Fluvastatin 1 (1.3) 0 (0) 1 (2.6) 1 (2.6) 0 (0)
Simvastatin 55 (69.6) 25 (62.5) 30 (76.9) 27 (71.1) 26 (70.3)
Atorvastatin 21 (26.6) 13 (32.5) 8 (20.5) 10 (26.3) 9 (24.3)
Rosuvastatin 2 (2.5) 2 (5.0) 0 (0) 0 (0) 2 (5.4)
Ezetimibe 1 (1.2) 0 (0) 1 (2.4) 1 (2.6) 0 (0)
Pre-morbid mRS <2 (%) † 60 (72.3) 26 (63.4) 34 (81.0) 27 (69.2) 28 (73.7)
ACE-R (/100) † 86.1 (7.7) 85.7 (8.1) 86.5 (7.4) 87.6 (7.7) 84.5 (7.3)
NIHSS (/42) 0.77 (1.1) 0.80 (1.1) 0.74 (1.1) 0.59 (0.9) 0.97 (1.3)
TACS (%) 6 (7.2) 3 (7.3) 3 (7.1) 4 (10.3) 2 (5.3)
Systolic BP (mmHg) † 147.1 (18.6) 145.9 (19.8) 148.3 (17.5) 147.6 (20.6) 147.9 (16.7)
<140 (%) 32 (38.6) 16 (39.0) 16 (38.1) 16 (41.0) 14 (36.8)
<125 (%) 9 (10.8) 6 (14.6) 3 (7.1) 5 (12.8) 3 (7.9)
Diastolic BP (mmHg) 82.1 (11.1) 82.5 (11.7) 81.7 (10.7) 83.3 (11.9) 81.2 (10.2)
Heart rate (bpm) 71.5 (14.2) 71.7 (14.9) 71.3 (13.8) 72.9 (16.4) 70.4 (11.5)
(Continued )
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Lipid measures
The mean total and LDL-cholesterol at baseline was 4.0/2.0 mmol/l and fell over 12 months on
treatment in the intensive but not guideline lipid-lowering group (Fig 2B). Mean total, LDL
and non-HDL cholesterol levels differed between the treatment groups at 6 months after ran-
domisation, and were lower by 0.54/0.44/0.44 mmol/l (2p = 0003/0003/0.024) in the intensive
group (S4 Table); potential explanations are given in S6 Table. The difference in LDL-c
between treatment groups was just over half the intended 1.0 mmol/l. The target LDL-choles-
terol levels of<1.3 mmol/l in the intensive group and<3.0 mmol/l in the control group were
achieved by 10 (28.6%) and 28 (87.5%) participants respectively.
Clinical and safety outcomes
80 (96%) patients had both vital status and the primary outcome recorded on at least one occa-
sion during treatment (Fig 1). Final follow-up was performed between 6 and 48 months, with
a median of 24 months (mean 24). When adjusted for randomisation variables, the primary
outcome (ACE-R) scores in the intensive BP lowering group and the guideline group did not
differ during treatment (MD in intensive BP lowering group lower by 3.6, 95% CI -9.7 to 2.4,
p = 024) (Table 2, Fig 3A, S7 Table). The effects of the treatments were consistent across all
pre-specified subgroups. There were no differences in secondary outcomes including cogni-
tion scores (MMSE, MoCA, TICS, trail making, Stroop, IQ-CODE, animal naming), rates of
dementia and vascular events, and functional outcome (mRS, BI), mood (ZDS) and quality of
life (HUS, EQ-VAS) (Table 2, S1 Fig). The overall rate of serious adverse events, fatal events,
and dementia and vascular events occurring by end of trial did not differ between the two BP
groups (S8–S10 Tables). The overall rate of dementia (2 cases) appeared lower than expected
(S6 & S9 Tables).
There was no difference in the primary outcome (ACE-R) during treatment between
patients randomised to intensive or guideline lipid lowering (MD in intensive lipid lowering
group higher by 4.4, 95% CI -2.1 to 10.9, p = 018) (Table 3, Fig 3B). However, in a post hoc
analysis, when comparing ACE-R scores at specific clinic visits, ACE-R was significantly
higher by 8.4 points (p = 0.032) at 6 months in patients randomised to intensive lipid lowering
(Fig 3B, S7 Table). The effects of the treatments were consistent across all pre-specified
Table 1. (Continued)
All Intensive BP Guideline BP Intensive lipids Guideline lipids
Lipids (mmol/l)
Total cholesterol † 4.0 (0.8) 3.9 (0.7) 4.1 (1.0) 4.0 (0.6) 4.0 (1.0)
Triglycerides 1.3 (0.6) 1.3 (0.6) 1.3 (0.6) 1.4 (0.7) 1.3 (0.6)
HDL-cholesterol 1.4 (0.5) 1.3 (0.4) 1.5 (0.6) 1.4 (0.4) 1.5 (0.6)
LDL-cholesterol 2.0 (0.7) 2.0 (0.5) 2.0 (0.8) 2.0 (0.5) 2.0 (0.8)
Non-HDL-cholesterol 2.6 (0.8) 2.6 (0.7) 2.6 (0.9) 2.6 (0.6) 2.5 (1.0)
Data are number (%), median [interquartile range] or mean (standard deviation).
† Minimisation variable–from June 2013 limited to age, ACE-R, systolic blood pressure and total cholesterol.
‡ Stratification variable;
¶ Protocol violation
Non-HDL-cholesterol = total cholesterol–HDL-cholesterol. ACE-R: Addenbrooke’s Cognitive Examination-revised; BP: blood pressure; bpm: beats per
minute; HDL: high density lipoprotein; IHD: ischaemic heart disease; LDL: low density lipoprotein; mRS: modified Rankin Scale; NIHSS: National Institutes
of Health Stroke Scale; PAD: peripheral arterial disease; IHD: current angina or previous angina or myocardial infarction; TACS: Total anterior circulation
syndrome.
doi:10.1371/journal.pone.0164608.t001
Intensive Blood Pressure and Lipid Lowering for Preventing Cognitive Decline after Stroke
PLOS ONE | DOI:10.1371/journal.pone.0164608 January 17, 2017 9 / 21
subgroups. The intensive lipid group had significantly higher cognition scores judged using
Trail Making, category fluency (animal naming) and Stroop accuracy (Table 3). Additionally,
the mRS was significantly lower, and EQ-VAS higher (S2 Fig), in patients randomised to
intensive lipid lowering. Although the total number of serious adverse events did not differ
between the groups, chest infections or pneumonia were less common in patients taking inten-
sive treatment (S8 Table). Rates of death, and dementia and vascular events did not differ
between the groups (S9 & S10 Tables).
In a qualitative end-of-trial assessment of patient views about the study, a number of themes
were expressed including having enjoyed being in the trial, hope that the results would help
Fig 2. Changes during follow-up in blood pressure and cholesterol by intensive vs guideline groups.
Data are mean and standard error of mean. (A) Systolic and diastolic blood pressure by intensive vs
guideline blood pressure lowering groups. (B) Total cholesterol and LDL-cholesterol by intensive vs guideline
lipid lowering groups.
doi:10.1371/journal.pone.0164608.g002
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others, sadness that the trial did not continue (as originally planned), and thanks for being in
the trial (S11 Table).
Discussion
This small partial factorial internal pilot trial in patients with recent stroke found that it was
feasible to lower BP intensively, and that intensive antihypertensive treatment, in comparison
Table 2. Primary and secondary cognition and other functional measures by treatment group: intensive vs guideline blood pressure lowering.
Comparison by multiple regression of mean on-treatment score with adjustment for baseline value and age, systolic blood pressure, total cholesterol, time
since stroke, treatment assignment (intensive vs lipid guideline lowering vs none).
Baseline Intensive Guideline Mean difference (95% CI) p
Follow-up (months) - 23.9 (8.0) 24.3 (10.3)
Clinic
ACE-R 86.1 (7.7) 80.8 (21.6) 84.4 (12.5) -3.6 (-9.7, 2.4) 0.24
MMSE 27.9 (2.0) 26.0 (6.5) 27.0 (3.8) -1.2 (-3.3, 0.8) 0.23
MoCA 24.0 (2.6) 22.6 (6.2) 23.2 (3.6) -0.7 (-2.6, 1.2) 0.46
TICS 24.1 (4.2) 22.1 (6.8) 23.2 (5.1) -1.8 (-3.8, 0.3) 0.086
Trail
A time (seconds) 57.1 (30.0) 79.1 (88.0) 68.5 (46.9) 13.2 (-13.6, 39.9) 0.33
A correct answers 24.6 (2.8) 22.9 (5.4) 24.1 (3.0) -1.4 (-3.1, 0.4) 0.13
B time (seconds) 155.5 (90.8) 178.4 (131.7) 165.8 (97.4) 6.9 (-27.5, 41.2) 0.70
B correct answers 22.1 (5.5) 21 (6.6) 22.0 (4.6) -1.6 (-3.8, 0.7) 0.17
Stroop
1 accuracy 23.3 (1.1) 21.5 (6.2) 22.6 (3.1) -1.5 (-3.4, 0.4) 0.12
1 time (seconds) 54.7 (20.6) 68.1 (65.2) 59.9 (39.0) 11.1 (-10.1, 32.2) 0.31
2 accuracy 23.4 (1.1) 21.9 (5.8) 22.7 (2.9) -1.2 (-3.1, 0.7) 0.20
2 time (seconds) 46.1 (20.7) 61.0 (63.8) 51.1 (41.4) 9.7 (-12.7, 32.1) 0.40
3 accuracy 20.0 (5.3) 18.4 (6.4) 19.3 (5.8) -1.4 (-3.7, 0.9) 0.23
3 time (seconds) 66.9 (34.5) 80.0 (61.9) 72.4 (50.3) 6.6 (-16.5, 29.8) 0.58
Interference accuracy -3.4 (5.4) -5.3 (6.6) -4.2 (5.6) -1.5 (-3.8, 0.9) 0.22
Interference time (seconds) 20.9 (22.1) 32.8 (44.2) 27.5 (29.9) 6.8 (-8.5, 22.0) 0.38
Informant (IQ-code) 3.0 (0.5) 3.1 (0.5) 3.0 (0.5) 0.1 (-0.1, 0.3) 0.23
Knafelc [37] 11.1 (10.0) 14.5 (20.0) 10.5 (9.7) 2.7 (-2.4, 7.8) 0.30
Animal naming 15.8 (5.5) 15.7 (6.7) 15.6 (5.2) 1.2 (-1.0, 3.4) 0.28
Telephone
MMSE 20.4 (1.8) 19.1 (5.3) 19.3 (4.9) -0.4 (-2.5, 1.7) 0.73
TICS 24.1 (4.2) 23.2 (7.4) 23.7 (7.3) -1.1 (-3.9, 1.7) 0.43
Function
mRS 1.1 (0.8) 1.3 (1.3) 1.4 (1.0) 0.0 (-0.4, 0.5) 0.90
Barthel Index 97.9 (4.8) 91.1 (22.7) 91.9 (13.4) -2.1 (-9.6, 5.4) 0.58
HUS (EQ-5D) 0.8 (0.2) 0.7 (0.2) 0.7 (0.2) 0.0 (-0.1, 0.1) 0.91
EQ-VAS 72.9 (17.6) 69.0 (22.0) 73.2 (14.5) -4.0 (-10.7, 2.7) 0.24
ZDS 45.6 (12.6) 47.5 (14.6) 45.9 (13.0) 3.1 (-1.8, 8.0) 0.22
ACE-R: Addenbrooke’s Cognitive Examination-R; EQ-VAS: EuroQoL-Visual Analogue Scale; HUS: Health Utility Status (from EuroQoL 5-dimensions);
MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; mRS: modified Rankin Scale; TICS: Telephone Interview Cognition Scale;
t-MMSE: telephone-Mini-Mental State Examination; ZDS: Zung Depression Scale.
Patients who died were assigned the following scores: -5: BI; -1: ACE-R, EQ-VAS, MMSE, MoCA, Stroop accuracy, TICS, Trail making A & B correct
answers, animal naming; 0: EQ-5D/HUS; 6: mRS; 102.5: ZDS; 301 secs: Stroop time alive censored at 300 secs; 403: Trail making A time; 601: Trail
making B time.
doi:10.1371/journal.pone.0164608.t002
Intensive Blood Pressure and Lipid Lowering for Preventing Cognitive Decline after Stroke
PLOS ONE | DOI:10.1371/journal.pone.0164608 January 17, 2017 11 / 21
with guideline BP lowering, reduced BP by around 11/6 mmHg but did not alter cognitive
impairment, as assessed using the ACE-R. Additionally there were no differences in other
measures of cognition, functional outcome, or vascular events. Intensive lipid lowering was
partially effective in comparison with guideline lowering, and reduced total and LDL-choles-
terol by around 0.5/0.4 mmol/l but did not alter ACE-R. Nevertheless, intensive lipid therapy
was associated with significant improvements in some secondary measures, including cogni-
tion (ACE-R at 6 months of treatment, trail making, category fluency, Stroop accuracy), func-
tion (mRS), and quality of life (EQ-VAS).
The potential mechanisms by which intensive BP lowering might benefit cognition are mul-
tiple, including reducing the risk of recurrent stroke, and increasing cerebral blood flow and
Fig 3. Changes in Addenbrooke’s Cognitive Examination-Revised score during follow-up for
intensive vs guideline groups. Data are mean and standard error of mean. (A) Intensive vs guideline
blood pressure lowering. (B) Intensive vs guideline lipid lowering.
doi:10.1371/journal.pone.0164608.g003
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so reducing the risk of hypotensive/low perfusion cerebral damage.[38] Lowering BP has been
associated with less cognitive impairment in several trials involving differing patient groups,
[4] including those with mid-life hypertension or chronic stroke. However, the results have
been inconsistent and assumed a linear relationship between change in BP and cognition.
Since the relationship between BP and stroke recurrence may be curvilinear or ‘J-shaped’,[39]
the same may also be true for the relationship between BP and cognition.[4] If so, a trial testing
intensity of BP lowering might achieve on-treatment BP levels that straddle the optimum BP
Table 3. Primary and secondary cognition and other functional measures by treatment group: intensive vs guideline lipid lowering. Comparison
by multiple regression of mean on-treatment score with adjustment for baseline value, age, systolic blood pressure, total cholesterol, time since stroke and
treatment assignment (intensive vs guideline BP lowering).
Outcome Baseline Intensive Guideline Mean difference (95% CI) p
Follow-up (months) - 24.6 (10.6) 22.9 (7.8)
Clinic
ACE-R 86.0 (7.6) 86.5 (11.7) 78.2 (22.2) 4.4 (-2.1, 10.9) 0.18
MMSE 27.9 (1.9) 27.6 (3.2) 25.3 (6.9) 1.9 (-0.3, 4.1) 0.085
MoCA 24.1 (2.6) 24.1 (3.4) 21.8 (6.3) 1.2 (-0.9, 3.2) 0.26
TICS 24.3 (4.2) 23.9 (4.5) 21.4 (7.4) 1.3 (-0.9, 3.5) 0.25
Trail A (time), (seconds) 58.1 (30.7) 60.2 (41.1) 89.6 (91.4) -28.9 (-56.7, -1.1) 0.045
Trail A (correct answers) 24.6 (2.9) 24.0 (2.9) 22.8 (5.7) 1.1 (-0.8, 2.9) 0.25
Trail B (time), (seconds) 151.5 (78.9) 149.3 (81.6) 195.7 (141.8) -25.8 (-61.2, 9.6) 0.15
Trail B (correct answers) 21.9 (5.7) 22.8 (3.7) 20.3 (7.0) 2.7 (0.3, 5.0) 0.025
Informant (IQ-code) 3.0 (0.5) 3.0 (0.5) 3.1 (0.5) -0.1 (-0.3, 0.1) 0.43
Knafelc 10.9 (9.9) 9.0 (7.7) 16.9 (21.2) -5.0 (-10.3, 0.3) 0.067
Animal naming 15.8 (5.4) 17.5 (5.4) 14.0 (6.1) 3.0 (0.8, 5.3) 0.008
Stroop
1 accuracy 23.2 (1.2) 22.9 (2.7) 20.9 (6.7) 1.7 (-0.3, 3.8) 0.092
1 time (seconds) 54.6 (20.5) 53.3 (29.5) 77.0 (71.9) -17.3 (-39.8, 5.3) 0.13
2 accuracy 23.4 (1.1) 23.0 (2.5) 21.4 (6.3) 1.4 (-0.6, 3.4) 0.16
2 time (seconds) 46.0 (19.9) 47.9 (28.0) 66.1 (73.5) -15.6 (-38.9, 7.6) 0.19
3 accuracy 20.0 (5.2) 20.5 (4.1) 17.0 (7.5) 2.7 (0.3, 5.1) 0.027
3 time (seconds) 67.3 (34.8) 66.0 (31.9) 87.6 (74.3) -20.5 (-44.2, 3.1) 0.088
Interference accuracy -3.4 (5.3) -3.1 (4.1) -6.5 (7.6) 2.7 (0.2, 5.1) 0.033
Interference time (seconds) 21.3 (22.3) 23.4 (23.7) 38.2 (49.1) -14.0 (-29.8, 1.8) 0.082
Telephone
MMSE 20.4 (1.7) 20.1 (4.0) 18.2 (6.1) 1.7 (-0.4, 3.9) 0.12
TICS 24.3 (4.2) 25.0 (6.4) 21.7 (8.2) 2.1 (-0.9, 5.1) 0.17
Function
mRS 1.1 (0.8) 1.1 (0.9) 1.6 (1.4) -0.5 (-1.0, 0.0) 0.036
Barthel Index 98.1 (4.1) 95.1 (12.0) 87.2 (23.6) 7.5 (-0.5, 15.4) 0.067
HUS (EQ-5D) 0.8 (0.2) 0.8 (0.2) 0.7 (0.2) 0.1 (0.0, 0.2) 0.084
EQ-VAS 73.0 (17.8) 75.3 (14.9) 65.9 (21.4) 8.6 (1.7, 15.5) 0.014
ZDS 45.6 (12.7) 45.5 (12.0) 48.4 (16.2) -3.0 (-8.2, 2.1) 0.25
ACE-R: Addenbrooke’s Cognitive Examination-R; EQ-VAS: EuroQoL-Visual Analogue Scale; HUS: Health Utility Status (from EuroQoL 5-dimensions);
MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; mRS: modified Rankin Scale; TICS: Telephone Interview Cognition Scale;
t-MMSE: telephone-Mini-Mental State Examination; ZDS: Zung Depression Scale.
Patients who died were assigned the following scores: -5: BI; -1: ACE-R, EQ-VAS, MMSE, MoCA, Stroop accuracy, TICS, Trail making A & B correct
answers, animal naming; 0: EQ-5D/HUS; 6: mRS; 102.5: ZDS; 301 secs: Stroop time alive censored at 300 secs; 403: Trail making A time; 601 Trail making
B time
doi:10.1371/journal.pone.0164608.t003
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level, or nadir of the relationship between BP and cognition; in this case, differences in cogni-
tion would not be expected between more and less intensive BP lowering. The neutral POD-
CAST results are compatible with this hypothesis with the nadir lying in the systolic BP range
of 130–140 mmHg although the exact level presumably varies by patient and stroke type.
Evidence that lowering cholesterol levels reduces cognitive impairment and dementia is
missing since both large and small trials have not identified any benefit.[4, 19, 20] PODCAST
confirms that intensive lipid lowering did not alter the primary measure of cognition. Never-
theless, a number of secondary outcomes were positive in favour of intensive lipid lowering
(following adjustment for baseline scores). Vascular cognitive impairment more commonly
affects executive function and sub-cortical processes such as response times rather than epi-
sodic memory and praxis (as seen in Alzheimer’s disease); in this context, intensive lipid low-
ering was associated with better scores on tests assessing executive function and attention,
including faster trail making (test A) and better accuracy on the Stroop, tests that identify cog-
nitive impairment in post stroke populations[40]
If lipid lowering does limit cognitive impairment and clinical dysfunction post stroke then
it is likely that the effect is mediated through statin intensity since differences in type and dose
of statin were the main difference between the treatment groups. In addition to lowering total-
c, LDL-c and non-HDL-c levels, statins have multimodal effects mediated through enhancing
endothelial nitric oxide synthase activity (with benefit on vascular integrity and function), and
attenuating inflammation, and smooth muscle cell and platelet function.[41, 42] In addition to
reducing vascular events, including stroke recurrence, other potential clinical effects of statins
include reducing dementia, cognitive impairment and pneumonia.[23]
PODCAST has several important limitations. First, it was far smaller than intended (83 of a
planned 600 participants). The low sample size was largely due to problems in recruiting suffi-
cient primary care and hospital sites due to a reluctance by healthcare commissioners to pay
for intensive lipid lowering drugs such as atorvastatin (this drug was on patent when the trial
commenced). This and other impediments to recruitment are discussed in a previous publica-
tion.[25] The funding of excess treatment costs (treatment-related costs in a clinical trial that
would continue after the trial finished if the treatment was effective) remains a significant
issue in the UK and this can delay the start of trials, and delay and limit recruitment.[43] In
this respect, the protocol could not be delivered but removal of this impediment related to
excess treatment costs might allow a similar protocol to be tested in a different funding envi-
ronment. Second, the small sample size meant that the study was very underpowered to detect
worthwhile clinical benefits. The neutral findings for the effect of intensive BP and lipid lower-
ing could simply reflect a false neutral finding (type II error) such that intensive lowering
might actually be beneficial. Although some secondary analyses were positive in favour of
intensive lipid lowering, these might reflect a false positive finding (type I error). Since second-
ary analyses were necessarily hypothesis generating, we did not adjust for multiplicity of test-
ing. Analyses were adjusted statistically for baseline stratification and minimisation factors so
minor differences in cognition scores at baseline are unlikely to have explained the positive
secondary findings.
Third, although the target difference in mean systolic BP between the intensive and guide-
line groups of 10 mmHg was achieved at 6 months, this was not maintained long-term and the
intensive group did not reach the absolute target of mean systolic BP <125 mmHg (S6 Table).
Treatment was not escalated by hospital investigators in the intensive group, manifest as a fail-
ure to increase the number of tablets and dose-adjusted number of tablets. A common concern
among investigators was whether the risk of falls would increase with intensive BP lowering
although this was not apparent in SAE rates in PODCAST and has not been observed in other
trials of intensive BP lowering. Fourth, neither of the two lipid targets were met; the difference
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in LDL-cholesterol between the two groups was 50–60% of planned. Originally, the target for
the intensive group was LDL-cholesterol <2.0 mmol/l but this was reduced to<1.3 mmol/l
when it became clear that the average LDL-c at baseline was already achieving target. Never-
theless, the new target was not achieved. Last, although some patients were followed for more
than two years, others were not and hence treatment may not have been given for long
enough.
In summary, intensive BP and lipid lowering appeared to have acceptable safety in those
patients where this was achieved but did not alter cognition in a population with a mean age of
74 with recent stroke and normal/near-normal cognition. The association between intensive
lipid lowering and improved scores for some secondary outcomes suggests further trials of
intensive lipid lowering are warranted.
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